What proteins and albumins in bronchoalveolar lavage fluid and serum could tell us in COVID-19 and influenza acute respiratory distress syndrome on mechanical ventilation patient - A prospective double center study
, , , , y
31 ene 2025
Acerca de este artículo
Categoría del artículo: Research Article
Publicado en línea: 31 ene 2025
Páginas: 64 - 69
Recibido: 08 mar 2024
Aceptado: 08 ene 2025
DOI: https://doi.org/10.2478/jccm-2025-0005
Palabras clave
© 2025 Anita Djurdjevic Svraka et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Fig. 1.
Fig 2.
Proteins and albumins values between the patient group and outcomes
| BAL albumin (g/L) | 1.63±1.35 | 1.55±1.46 | 0.07±0.07 | <0.001 | 0.58±1.11 | 1.71±1.34 | <0.001 |
| BAL total protein (g/L) | 1.53±0.71 | 1.47±0.71 | 0.43±0.35 | <0.001 | 0.85±0.71 | 1.52±0.72 | <0.001 |
| Serum albumin (g/L) | 28.73±4.97 | 31.93±4.85 | 38.43±4.03 | <0.001 | 36.09±5.17 | 28.61±4.89 | <0.001 |
Demographic variables, days of invasive mechanical ventilation and outcome between two groups of ARDS patients
| Patients (n) | 30 | 14 | NA | 13 (29.5%) | 31(70.5%) | NA |
| Age (median, IQR) | 72.5 (35–83) | 62 (34–69) | <0.01 | 60 (35–70) | 72 (34–83) | <0.01 |
| Male (n,%) | 17 (56.7%) | 7(50%) | 0.7 | 9 (37.5%) | 15 (62.5%) | 0.24 |
| COPD (n,%) | 3 (10%) | 3 (21.4%) | 0.43 | 1 (16.7%) | 5 (83.3%) | 0.57 |
| CV diseases (n,%) | 18 (60%) | 6 (42.9%) | 0.33 | 6 (25%) | 18 (75%) | 0.51 |
| Diabetes (n,%) | 6 (20%) | 2 (14%) | 0.71 | 1 (12.5%) | 7 (87.5%) | 0.35 |
| CMV days (median, IQR) | 13 (1–31) | 14 (1–34) | 0.27 | 13 (1–39) | 13 (1–39) | 0.5 |
| Survivors (n,&) | 5 (16.7%) | 8 (57.1%) | <0.01 | NA | NA | NA |